123 related articles for article (PubMed ID: 36926936)
41. Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP; Lichtenstein GR
J Clin Gastroenterol; 2016 Apr; 50(4):318-25. PubMed ID: 26368296
[TBL] [Abstract][Full Text] [Related]
42. Mesalazine for ulcerative colitis complicated with diabetic nephropathy.
Oshimoto H; Okamura S; Onozato Y; Ishihara H; Mori M
J Gastroenterol; 2001 Dec; 36(12):863-4. PubMed ID: 11777217
[No Abstract] [Full Text] [Related]
43. Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects.
Park SK; Ye BD; Yang SK; Kim SO; Kim J; Kim JW; Park SH; Yang DH; Jung KW; Kim KJ; Byeon JS; Myung SJ; Kim JH
J Crohns Colitis; 2014 Oct; 8(10):1254-60. PubMed ID: 24662395
[TBL] [Abstract][Full Text] [Related]
44. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
[TBL] [Abstract][Full Text] [Related]
45. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
46. Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study.
Levine A; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; Shabat CS; Focht G; Shachmon E; Boaz M; On A; Turner D
J Crohns Colitis; 2017 Aug; 11(8):970-974. PubMed ID: 28369299
[TBL] [Abstract][Full Text] [Related]
47. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
Miner P; Hanauer S; Robinson M; Schwartz J; Arora S
Dig Dis Sci; 1995 Feb; 40(2):296-304. PubMed ID: 7851193
[TBL] [Abstract][Full Text] [Related]
48. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
49. Mesalazine-probiotics beads for acetic acid experimental colitis: formulation and characterization of a promising new therapeutic strategy for ulcerative colitis.
Vishwakarma N; Ganeshpurkar A; Pandey V; Dubey N; Bansal D
Drug Deliv; 2015 Jan; 22(1):94-9. PubMed ID: 24491122
[TBL] [Abstract][Full Text] [Related]
50. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.
Watanabe M; Hanai H; Nishino H; Yokoyama T; Terada T; Suzuki Y
Inflamm Bowel Dis; 2013 Jul; 19(8):1681-90. PubMed ID: 23624890
[TBL] [Abstract][Full Text] [Related]
51. Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.
Vrij AA; Oberndorff-Klein-Woolthuis A; Dijkstra G; de Jong AE; Wagenvoord R; Hemker HC; Stockbrügger RW
J Thromb Thrombolysis; 2007 Oct; 24(2):175-82. PubMed ID: 17308963
[TBL] [Abstract][Full Text] [Related]
52. Ulcerative colitis occurring in the course of rheumatoid arthritis: a case successfully treated with mesalamine enema.
Sugisaki K; Honma F; Iwadate H; Shio K; Shioya Y; Fukaya E; Sato K; Saito H; Sekine H; Kobayashi H; Orikasa H; Watanabe H; Sato Y
Intern Med; 2004 Nov; 43(11):1046-50. PubMed ID: 15609700
[TBL] [Abstract][Full Text] [Related]
53. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
Keil R; Wasserbauer M; Zádorová Z; Kojecký V; Hlava Š; Št'ovíček J; Chudý J; Roznětinská M; Drábek J; Kubišová N; Lochmannová J
Scand J Gastroenterol; 2018 Apr; 53(4):459-465. PubMed ID: 29560753
[TBL] [Abstract][Full Text] [Related]
54. Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem.
Protic M; Markovic S; Tarabar D
Dig Dis; 2017; 35(1-2):134-138. PubMed ID: 28147377
[TBL] [Abstract][Full Text] [Related]
55. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis.
Irvine EJ; Yeh CH; Ramsey D; Stirling AL; Higgins PD
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1278-86. PubMed ID: 18808446
[TBL] [Abstract][Full Text] [Related]
56. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Pica R; Cassieri C; Cocco A; Zippi M; Marcheggiano A; De Nitto D; Avallone EV; Crispino P; Occhigrossi G; Paoluzi P
Dig Liver Dis; 2015 Nov; 47(11):933-7. PubMed ID: 26391602
[TBL] [Abstract][Full Text] [Related]
57. Mesalazine induced interstitial pneumonitis in the COVID era.
Aparicio Serrano A; Gallego Jiménez E; Castro Rodríguez J; Soto Escribano P; Iglesias Flores E; Marín Pedrosa S; Benítez JM
Rev Esp Enferm Dig; 2022 Jul; 114(7):429-430. PubMed ID: 35199533
[TBL] [Abstract][Full Text] [Related]
58. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
[TBL] [Abstract][Full Text] [Related]
60. Giant pyoderma gangrenosum in a patient with ulcerative colitis: A case report.
Niu R; Zheng J; Ding D; Kuang W; Lu F; Yin X
Medicine (Baltimore); 2020 Feb; 99(6):e18795. PubMed ID: 32028391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
